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ABSTRACT 
On the basis of literature survey compound 2-(1H-benzo[d]imidazole-1-yl)-N-(3-cyano-4,6-diphenylpyridin-2-yl) acetamide (6) was 
designed. Compound 6 and imipramine were virtually studied for their antidepressant activity by performing docking studies using 
Molegro Virtual Docker (MVD-2013, 6.0) on human MAO (PDB ID: 2BXS). Docking studies revealed its potential antidepressant 
effect as compared with imipramine. The result of docking study was validated by synthesizing and screening the compound for it’s 
in vivo antidepressant activity following forced swim test and locomotor activity using actophotometer. Finally, we conclude that the 
docking result and experimental results are in good agreement. 
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INTRODUCTION: 
Depression is a psychological disorder with a low mood, 
loss of interest, affecting sense of well being, anorexia, 
low energy, poor concentration and impaired sleep. This 
problem may become recurrent and even lead to suicide. 
According to WHO report depression have become 
serious health problem affecting about 121 million 
people worldwide.
[1]
 
Pathophysiology of depression is not clearly understood, 
but some hypothesis suggests that depression and 
maniac disorder may be caused by lack of nor adrenaline 
and serotonin. Most of the synthetic drugs used as an 
antidepressant act on biogenic amines of the brain. Thus 
leading to increasing their concentration in respective 
part of brain. MAO enzyme causes deactivation of 
biogenic amines. Thus by inhibiting the MAO 
intracellular concentration of endogenous amines may 
be increased, which seems to be the major cause of 
antidepressant effect.  
MAO inhibitors available in the market have serious 
side effects like hypertension, tremors, muscle rigidity 
and seizures
[2]
. Hence there is a need of potent 
antidepressant with less or no side effects. 
In medicinal chemistry heterocyclic compound pyridine 
has been found to be of utmost importance. Pyridine and 
related compounds had exhibited various biological 
activities like antimicrobial, anti-inflammatory, 
anticancer and anti-tubercular activity.
[3] 
 
On the basis of above observations we decided to design 
a novel pyridine derivative, to study it’s binding 
interactions with MAO enzyme by docking studies and 
to screen the compound for antidepressant activity. 
MATERIALS AND METHODS  
Chemicals: 
All the solvents and chemicals were purchased from SD 
Fine Chem Ltd, Kemphasol, Molychem, and Fisher 
Scientific Pvt. Ltd. Melting Point of synthesized 
compounds were determined by Thiele’s melting point 
apparatus and were uncorrected. IR Spectra was 
recorded on Schimadzu IR AFFINITY -1 
spectrophotometer by using KBr pellets. The 
1
H NMR 
was recorded on BruckerAvance II 400 NMR 
Spectrometer by using DMSO as a solvent and Tetra 
Methyl Silane as internal standard, chemical shifts are 
expressed as δ values in ppm. 
Animals: 
Male albino mice of 20-25g were obtained from animal 
house of PES’s Rajaram and Tarabai Bandekar college 
of Pharmacy, Farmagudi, Goa.  
Molecular docking methodology 
The molecular docking study was performed using 
Molegro Virtual Docker (MVD-2013, 6.0). The crystal 
structure of the monoamine oxidase - A co-crystallized 
with clorgyline inhibitor was downloaded from Protein 
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Data Bank (PDB ID: 2BXS). Molecular docking study 
of the synthesized compound/ligand was performed in 
order to understand the various interactions between the 
ligand and enzyme active site in detail. The molecular 
docking study was performed for the target compound 
by using MVD-2013 (Version: 6.0).  
The synthesized compound was built using Chemdraw 
11.0. The 2D structure was then converted into energy 
minimized 3D structure and was saved as MDL Molfile 
(.mol2). The coordinate file and crystal structure of 
monoamine oxidase - A was obtained from the RCSB 
PDB website (PDB ID: 2BXS). The protein file was 
prepared by the removal of water molecules, addition of 
polar hydrogens and removal of other bound ligands. In 
the present study, the binding site was selected based on 
the amino acid residues, which are involved in binding 
with clorgyline inhibitor of MAO-A as obtained from 
protein data bank, which would be considered as the 
probable best accurate region as it is solved by 
experimental crystallographic data. The docking 
protocol was carried out for the synthesized compound 
as listed in Table 1 using MVD-2013 (6.0) software 
using the standard operating procedures. 
Synthesis:  
Synthesis of 2-amino-4,6-diphenylpyridine-3-
carbonitrile (4):  
A mixture of benzaldehyde (1, 0.10612 g, 1 mmol), 
acetophenone (2, 0.12015 g, 1 mmol), malononitrile (3, 
0.06606 g, 1 mmol) and ammonium acetate (0.6166 g, 8 
mmol) were dissolved in toluene (20 mL) and refluxed 
for about 6 h. The completion of the reaction was 
monitored by TLC using Chloroform : Ethanol, (0.5:1) 
as the mobile phase. The resulting solid formed was 
filtered, washed with ethanol and recrystallized with 
acetone to get the pure product (4).  
Synthesis of 2- chloro-N-(3-cyano-4,6-
diphenylpyridin-2-yl)acetamide (5):  
A mixture of 2-amino-4,6-diphenylpyridine-3-
carbonitrile (4, 1.45 g, 1 mmol), triethylamine (1.08 g, 2 
mmol) and chloroacetyl chloride (1.2 g, 2 mmol) was 
dissolved in dichloromethane (20 mL) and stirred for 12 
h. The completion of the reaction was monitored by 
TLC using Chloroform: Methanol (0.5:1) as the mobile 
phase. The solid thus formed was filtered, washed with 
water, dried and recrystallized from ethanol to get the 
pure compound.  
Synthesis of 2-(1H-benzo[d]imidazole-1-yl)-N-(3-
cyano-4,6-diphenylpyridin-2-yl) acetamide (6):  
A mixture of potassium carbonate (0.34 g, 2.5 mmol) 
and benzimidazole (2 mmol) in dry acetone (20 mL) 
were stirred on magnetic stirrer for 1 h. The above 
solution was then added to 2-chloro-N-(3-cyano-4,6-
diphenylpyridin-2yl)acetamide (5, 0.43 g, 1.25 mmol) 
and refluxed in round bottom flask for 6-13 h. The 
completion of reaction was monitored by TLC. After the 
reaction completion the solvent was removed by vacuum 
distillation and residue was treated with sodium 
bicarbonate (5 % w/v) to remove acid impurities. The 
residue was washed with water, dried and recrystallized 
from ethanol.   
2-Amino-4,6-diphenylpyridine-3-carbonitrile (4) 
Yield: 50%, m. p.: 182
o
C, IR (KBr, cm
-1
): 3464.15 
(NH), 3302.13,  3176.76 (C-H aromatic), 2206.57 (CN ), 
1573.91 (C=C); 
1
HNMR (400 MHz, CDCl3, δ ppm): 
7.20 (s, 1H, Ar-H), 7.45-7.49 (m, 3H, Ar-H),7.507.54 
(m, 3H,Ar-H), 7.62-7.64 (m, 2H, Ar-H), 7.988.00 (m, 
2H, Ar-H), 5.41 (s, 2H, N-H). 
2-Chloro-N-(3-cyano-4,6-diphenylpyridin-2-
yl)acetamide (5) 
Yield: 64%, m. p.: 172
o
C, IR (KBr, cm
-1
): 3464.15 
(NH), 3302.13,  3132.740 (C-H aromatic), 2206.57 (CN 
), 1639.49 (C=O), 1604.77 (C=C), 754.17 (C-Cl); 
1
HNMR (400 MHz, CDCl3, δ ppm): 7.21 (s, 1H, Ar-H), 
7.45-7.48 (m, 3H, Ar-H),7.49-7.54 (m, 3H, Ar-H), 
7.627.65 (m, 2H, Ar-H),7.99-8.01 (m, 2H, Ar-H), 5.36 
(s, 1H, NH), 3.68 (s, 2H, CH2). 
2-(1H-Benzo[d]imidazol-1-yl)-N-(3-cyano-4,6-
diphenylpyridin-2-yl)acetamide (6) 
Yield: 66%, m. p.: 149
o
C, IR (KBr, cm
-1
): 3464.15 (N-
H), 3176.76 (C-H aromatic), 2206.57 (CN), 1637.56 
(C=O amide), 1573.91 (C=N); 
1
HNMR (400 MHz, 
DMSO- d6, δ ppm): 7.22 (s, 1H, Ar-H), 7.39-7.46 (m, 
5H, Ar-H),7.47-7.51 (m, 3H, Ar-H), 7.53-7.59 (m, 5H, 
Ar-H), 7.61-7.84 (m, 2H, Ar-H), 5.38 (s, 1H, NH), 3.69 
(s, 2H, CH2). 
Scheme 1. Synthesis of pyridine derivative  
 
In-vivo studies:  
Animals:  
Male albino mice weighing between 20-25 gm were 
used. Animals were maintained under standard 
conditions in the animal house of  Ponda Eduation 
Society’s Rajaram and Tarabai Bandekar College of 
Pharmacy, Goa. The animals were housed at 24+ 2 
0
C 
with 12 :12 h light and dark cycle. They had free access 
to food and water. The animals were acclimatised for a 
period of seven days before study. The study was 
approved by Institutional Animal Ethics Committee with 
resolution number PESRTBCOP/IAEC;clear/2015-
16/R-12 
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Acute toxicity studies: 
Acute oral toxicity studies of compound 6 was carried 
out on Swiss albino mice weighing between 25-30g 
according to OECD guideline No. 423. The animals 
were then observed continuously for the first 4 h for any 
behavioural changes and for mortality if any at the end 
of 72 h.The doses were found to be safe at 200 mg/kg 
when administered orally and is used for antidepressant 
activity and locomotor activity. 
Antidepressant activity  
Antidepressant activity of compound 6 was evaluated by 
force swimming test
[5]
 and locomotor activity using 
actophotometer and was compared with reference 
standard imipramine. A total of 18 animals were used in 
study. They were divided into 3 groups of 6 animals 
each.  
Treatment groups  
Group 1: Normal control (saline)  
Group 2: Compound 6 (200 mg/kg, p.o.)  
Group 3: Imipramine (10 mg/kg, p.o.)
[4] 
Forced swim test: Animals were moved from animal 
house to laboratory in their own cages and allowed to 
adapt to the laboratory conditions for 1-2 hr. Mice were 
individually forced to swim in bucket (25 × 25cm) 
containing fresh water to a height of 15 cm and 
maintained at 26°±1°C. At this height of water, animals 
were not able to support themselves by touching the 
bottom or the side walls of the chamber with their hind-
paws or tail. Water in the chamber was changed after 
subjecting each animal to Forced swimming test because 
“used water” has been shown to alter the behavior. Each 
animal showed vigorous movement during initial 2 min 
period of the test. The duration of immobility was 
manually recorded during the next 4 min of the total 6 
min testing period. 
Locomotor activity:The locomotor activity was 
monitored by using actophotometer. Before subjecting 
the animal for locomotor task they were individually 
placed in activity meter and the total activity count was 
registered for 10 min. the locomotor activity was 
expressed in terms of total photo beams count / 10 min 
per animal. 
RESULTS AND DISCUSSION  
Docking study 
Molecular docking study of compound 6 and imipramine 
was performed using Molegro Virtual Docker (MVD-
2013, 6.0). The crystal structure of mono amine oxidase 
- A was obtained from the RCSB PDB website (PDB 
ID: 2BXS). The PDB structure 2BXS bound to the 
inhibitor clorgyline shows a true binding site for each of 
the subunits. An essential feature of the binding site is 
the conservation of hydrogen bondings and the aromatic 
π-π stacking interactions. The active pocket consists of 
amino acid residues such as Ala68, Ala409, Arg51, 
Asp64, Cys406, Glu436, Gly49, Gly67, Gly301, 
Gly405, Gly426, Gly447, Ile23, Lys305, Met300, 
Met445, Phe352, Ser223, Ser403, Thr52, Thr183, 
Thr435, Trp397, Tyr69, Tyr407, Val65 and Val182. 
Hence, to identify other residual interactions of the 
compound 6, a grid box of 10.0 Ǻ was constructed. 
Clorgyline being a known inhibitor, the center of this 
site was considered as the center of  search space for 
docking.  
The docking results reveals that for compound 6, the 
Mol-Dock score was -183.47, while for reference 
standard imipramine it is -112.101. The best orientation 
poses of the docked compound 6 and imipramine are 
shown in Figure 1. It was clearly observed that 
imipramine exhibited one hydrogen bond with Tyr407, 
while compound 6 displayed four hydrogen bonds with 
Tyr407, Tyr69, Ala68 and Met445.            
Chemistry 
The title compound was synthesised as outlined in the 
Scheme 1. The compound 4 was obtained by 
condensation and cycloaddition of benzaldehyde, 
acetophenone and malononitrile. Compound 4 was 
further treated with chloroacetyl chloride to afford 
compound 5. Finally, compound 5 was reacted with 
benzimidazole to afford the title compound 6.The 
formation of all the synthesized compounds were 
ascertained by IR and 
1
HNMR spectral data. 
  
Table 1: Moldock scores and other energy calculations of compound 6 and imipramine by MVD-2013 against 
2BXS   
Compound 
MolDock 
Score 
(Kcal/mol) 
E- Inter 
(Protein-
ligand) 
H Bond 
No. 
  
Heavy 
Atoms 
count LE1 LE3 
Docking 
Score 
(Kcal/mol) 
Rerank Score 
(Kcal/mol) 
Imipramine -112.101 -134.749 1 
-
1.94795 21 -5.33816 -4.26125 -111.345 -89.4863 
6 -183.47 -206.105 4 
-
7.39705 33 -5.55969 -3.82814 -180.712 -126.329 
 
In-vivo activity:  
Forced swim test: 
The antidepresant activity of compound 6 was carried by 
force swim test and the results are depicted in Figure 2. 
In this test the reference standard imipramine at a dose 
level of 10 mg/kg showed more significant decrease 
in the immobility time to 71.00±4.171 as compared to 
control (169.2±4.826). The synthesized pyridine 
derivative showed a significant decrease in the 
immobility time to 130.0±8.278 as compared to control.
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Locomotor activity: 
The locomotor activity of compound 6 was carried by 
using actophotometer and results are shown in Figure 3. 
The test results showed that the reference standard drug 
imipramine at a dose level of 20mg/kg produced 
increased in the locomotor activity (621.8±18.13) 
compared to control (307.3±12.71). The synthesized 
pyridine derivative showed a significant increase 
in the locomotor activity to 585.8±24.88 as compared to 
control. 
 
CONCLUSION: 
Compound 6 exhibited better antidepressant potential and the docking study results are validated by in-vivo activity.  
                  
Figure 1. Showing the compounds docked in best of its conformation into the binding site of 2BXS (A) binding mode of imipramine 
forming 1H bond with Tyr407; (B) binding mode of compound 6 forming forming 4H bonds with Tyr407, Ala68, Tyr69 and 
Met445. 
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Figure 2 and 3: Values are expressed as mean±SEM.  Number of animals=6. *** P<0.001 
compared to respective vehicle treated control group. Results were analyzed by one-way ANOVA fallowed by Dunnett’s multiple 
comparison test. 
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